news.cision.com

YIT Corporation News, May 22, 2017 at 10:00 a.m.The most important life in the city takes place between buildings and not indoors, says urban developer Janne Viitamies. This has also been taken into account in the new urban centre, Tripla. Street space is a natural part of the shopping centre, and passers-by do not need to know whether they are in or outside the mall. Many of us here in Finland like to meet others outdoors—whether for a morning coffee or brunch, after-work conversation with drinks or just to enjoy an ice-cream, watching people passing by. The best thing about the city

Ericsson and MGTS improve network performance with Preemptive Support

· Ericsson to monitor the Moscow City Telephone Network, anticipate emerging issues and prevent critical network incidents · A specialized data analytics module is used to monitor Russia's largest urban telecom network and provide actionable recommendations to the operator · This service delivers insights that help operators to improve customer experience, reduce churn and increase operations and maintenance efficiency Ericsson (NASDAQ: ERIC) and Moscow City Telephone Network (MGTS) have signed a Preemptive Support contract whereby Ericsson will monitor Russia's largest urban

Detection Technology Plc - Managers' Transactions

Detection Technology Plc Managers' Transactions 22 May 2017 at 10:00 (EEST) Detection Technology Plc - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Utela, Kai Position: Other senior manager Issuer: Detection Technology Plc LEI: 743700IXKYKNXJ6BFL39 Notification type: INITIAL NOTIFICATION Reference number: 743700IXKYKNXJ6BFL39_20170520155937_7 ____________________________________________ Transaction date: 2017-05-19 Venue: FIRST NORTH FINLAND (FNFI) Instrument type: SHARE

SimCorp Strengthens Asian Presence with New Asia Pacific Head

Mon, May 22, 2017 08:47 CET

SimCorp , a leading provider of investment management solutions and services for the global financial services industry, today announced the appointment of Oliver Johnson as Managing Director, Asia Pacific. Oliver joined SimCorp in May, will be based in Singapore, and reports to Jochen Müller, SimCorp’s Executive Vice-President, EMEA and Asia Pacific. Reinforcing SimCorp’s growing Asia Pacific footprint, Oliver will be responsible for overseeing all management, operations, sales and distribution, plus enhancing

CORRECTION: Kværner ASA: Mandatory notification of trade primary insiders

This is a correction of the announcement from 08:28 22.05.2017 CEST. Reason for the correction: 22 May 2017 - Shares awarded to employees under the variable pay programme 2014. Kværner ASA has awarded 1 431 981 shares to employees at a price of NOK 5.82 per share under the variable pay programme 2014. The share price was calculated 30 April 2015 as set out in the Statement of executive remuneration approved by the Annual General Meeting 2015. Please see attachment for details of about the number of shares awarded to primary insiders. After the share allocation, Kværner ASA holds 2

SpiffX strike strategic UK distribution deal with Eclectic Media Network

Mon, May 22, 2017 08:31 CET

SpiffX announces a strategic deal with Eclectic Media Network to gain distribution of its Sport Random Games in the UK market. The deal mean that SpiffX will integrate its consumer products, Take5Live and other Sport Random Games, on Eclectic Media Networks technical platform. -The deal with Eclectic does not only opens up distribution in and access to the big and important UK market, it also gives us an collaboration with a very professional partner that has identified the enormous potential of casino-sport betting hybrid games, a segment we at SpiffX calls “Sport Random Games”. We

Ratos AB: Ratos divests Nebula to Telia Company

Press release 22 May 2017 Ratos has signed an agreement to divest all of its shares in its subsidiary Nebula - Finland's leading provider of cloud services to small and medium-sized companies - to Telia Company for EUR 165m (enterprise value). The divestment generates a net exit gain of approximately SEK 500m, an average annual return (IRR) of approximately 37% and a money multiple of 3.3x. Nebula is a market leading provider of cloud services, managed services, and network services to small and medium-sized enterprises in the Finnish market. The company has approximately 44,000

Diamyd Medical submits application to the Medical Products Agency for the DIAGNODE-2 trial

Diamyd Medical today announced that the Company has submitted an application to the Swedish Medical Products Agency to conduct DIAGNODE-2, a pivotal follow-up clinical trial in children and adolescents recently diagnosed with type 1 diabetes. The placebo-controlled Phase II trial will investigate an innovative and patent-pending concept, where the diabetes vaccine Diamyd® is administered directly into the lymph nodes. The trial will be conducted in Sweden, Spain and the Czech Republic at selected diabetes clinics, with established contacts and interests to achieve the best possible

Telia Company acquires Finnish ICT service company Nebula

Telia Company acquires 100 percent of Nebula Top Oy, a Finnish provider of cloud services to SME and SoHo customers, at an enterprise value of EUR 165 million on a cash and debt free basis. The transaction will ensure Telia’s competitive position in the SME and SoHo segments.Nebula Top Oy was founded in 1997 and offers highly automated and standardized cloud infrastructure services with a strong customer centric model. Nebula’s 145 employees serve a customer base of approximately 44,000 who generate 90 percent subscription-based recurring revenues. In 2016 Nebula reported net sales of

TalkPool increases its order intake from large European telecom operators

Talkpool has during late 2016 and the beginning of 2017 celebrated break-throughs with several European network operators such as Deutsche Telekom, Belgacom, Vodafone and Orange – and order volumes have rapidly grown during the first four months of 2017. This client segment, which represented no revenues a year ago, is now TalkPool’s fastest growing customer group and biggest opportunity.“TalkPool’s order intake from clients in Europe increased in the second half of 2016 and has continued to accelerate during the first four months of 2017 while order levels from clients in Africa and the

Biohit Acetium® lozenge is a highly effective means to stop smoking – results confirmed in a new large-scale trial

Mon, May 22, 2017 08:28 CET

Biohit Oyj Inside Information May 22, 2017 at 9:30 am local time (EEST) The second smoking intervention study started in 2016 with Biohit Acetium lozenge has been completed confirming the efficacy of Acetium lozenge as an effective way to assist in smoking cessation. This new trial was designed to be adequately powered to confirm the results of the first intervention study indicating that Acetium is a potential new tool in assisting smoking cessation (1). This novel indication of Acetium lozenge is based on its capacity to effectively bind cigarette smoke-derived acetaldehyde in the

Kværner ASA: Shareholdings 22 May 2017

22 May 2017 - Kvaerner has awarded the following primary insiders shares 22 May 2017: Name Name No. of shares No. of shares following allocationHenrik SVP Corporate 108 553 113 534Inadomi SupportElly EVP Process 45 734 45 734Bjerknes SolutionsIngrid VP IR & 38 424 54 685Aarsnes CommunicationsArnt SVP Business 64 497 88 691Knudsen DevelopmentHans EVP Concrete & 46 184 57 800Petter New SolutionsMølmenSteinar Steinar 61 706 75 706Røgenes

CEVT selects Zalaris for SuccessFactors-based cloud services to growing workforce

Mon, May 22, 2017 08:09 CET

Zalaris ASA has signed a five-year contract to deliver cloud services to China Euro Vehicle Technology (CEVT), a Sweden-based automotive innovator employing some 2 000 employees and contractors.Zalaris ASA continues to build on its success as a provider of SAP SuccessFactors-based outsourcing and cloud services through the agreement with CEVT, a Geely Group-owned development center focused on finding smarter ways to build cars by pushing the boundaries of virtual engineering. The Zhejiang Geely Group owns both Volvo Cars Group and CEVT – both with strong industrial footprint and history in

BerGenBio Announces Start of Randomised Phase I/II Trial Assessing Selective AXL Inhibitor BGB324 in Combination with Current Therapies in Melanoma

Bergen, Norway, May 22 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors to treat multiple cancer indications, announces that the first patients have been dosed and continue on therapy in a Phase I/II randomised trial evaluating the addition of BerGenBio’s highly selective, potent and orally bio-available AXL inhibitor BGB324 to standard of care treatments in patients with advanced, non-resectable or metastatic melanoma. The trial, which is sponsored by Haukeland University Hospital (Bergen, Norway)

One Sea - Autonomous Maritime Ecosystem introduced roadmaps to autonomous shipping

Top players from marine and IT-industry have teamed up to jointly develop world's first system of autonomous ships. The shared vision for the ecosystem partners is to enable fully remote controlled vessels in the Baltic Sea in three years and to achieve autonomous commercial maritime traffic by 2025.The One Sea ecosystem, founded in 2016, represents exceptionally advanced co-creation where global leaders in their industries work to reach their joint goal of autonomous traffic. The founding partners in the One Sea – Autonomous Maritime Ecosystem are ABB, Cargotec (MacGregor and Kalmar),

Wilson Therapeutics Strengthens its Board of Directors by the Appointments of Birgitte Volck and Björn Odlander

The Annual General Meeting of Wilson Therapeutics AB (publ), has elected Dr. Birgitte Volck and Dr. Björn Odlander as new members of the Board of Directors. Dr. Birgitte Volck is Senior Vice President, Head of R&D Rare Disease at GlaxoSmithKline headquarters in London, UK. Dr. Volck has extensive development experience with orphan drugs and more than 17 years of experience from senior roles in the biotech industry. Prior to GlaxoSmithKline, Dr. Volck served as Chief Medical Officer and Head of Development at Sobi and has also held senior roles at Amgen, Genzyme and Pharmexa. Throughout

GBO announces final outcome in the offer for Vigmed

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, New Zealand, South Africa or the United States or in any other jurisdictions where such offer pursuant to legislation and regulations in such relevant jurisdictions would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important notice” at the end of this

CEVT selects Zalaris for SuccessFactors-based cloud services to growing workforce